Buy SPARC, says Siddhartha Chaterjee

Buy Sun Pharma Advanced Research Company (SPARC), says Siddhartha Chaterjee of Trustline Securities.

Chaterjee told CNBC-TV18, "SPARC is a research company from the Sun Pharma group. Last Friday SPARC crossed 200 days moving average with expanding volume. As you would all know that 200 days moving average is a particular average above which if prices maintain we categories them as bull stock. Our buy recommendation on SPARC with a stoploss of Rs 83 for target of Rs 88.